What question did this study set out to answer?

This research investigates the correlation between minimal residual disease (MRD) negativity and clinical outcomes in relapsed/refractory follicular lymphoma treated with epcoritamab.

July 12, 2026Blood AdvancesOpen Access

MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FL

View Full Paper

Ask AI

Bookmark

Authors

IAIşıl AltıntaşGenmab (Netherlands)CMChristopher MorehouseGenmab (United States)EFElena FavaroGenmab (Denmark)

Discussion

Member takes

Implication

Randomized trial shows improved progression-free survival in relapsed/refractory follicular lymphoma, indicating value of MRD analysis.

Key Points

This research investigates the correlation between minimal residual disease (MRD) negativity and clinical outcomes in relapsed/refractory follicular lymphoma treated with epcoritamab.
Evaluated MRD status using peripheral blood mononuclear cells (PBMCs) and circulating tumor DNA (ctDNA) at specified time points in NCT03625037 trial.
Assessed progression-free survival (PFS) based on MRD status by the clonoSEQ® assay and overall response evaluated by PET/CT.
Performed multivariable analyses to adjust for baseline clinical risk factors.
Most MRD-evaluable patients reached MRD-negativity by cycle 3 day 1, correlated with prolonged PFS (median not reached).
Patients with MRD-positive status had shorter PFS compared to MRD-negative patients, regardless of disease features.
At week 12 and week 18, MRD-negative responders showed significantly improved PFS after adjusting for baseline risk factors.

Cite This Study

Altıntaş et al. (2026) studied this question.

synapsesocial.com/papers/6a5333754f7abc118adee106 https://doi.org/10.1182/bloodadvances.2025017565

View Full Paper

Ask AI

Bookmark

MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FL

Discussion

Member takes

Implication

Key Points

Cite This Study

MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FL

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider